CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nvelop Therapeutics, a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases. The company’s approach has the potential to enable highly efficient and cell-specific delivery of a broad set of therapeutic cargoes..

马萨诸塞州剑桥市。-（商业新闻短讯）--Nvelop Therapeutics是一家生物技术公司，它设计了可编程的非病毒载体，用于体内递送治疗性货物，今天正式宣布推出该产品，以开发针对多种疾病的下一代遗传药物。该公司的方法有可能实现高效和细胞特异性递送广泛的治疗货物。

“The field of genetic medicine is significantly limited by the challenge of efficiently delivering therapeutic cargoes to many types of target cells in vivo,” said Jeff Walsh, Nvelop’s Chief Executive Officer. “With the combination of best-in-class technologies, scientific co-founders with a deep track record in cell and gene therapy, and a team that has pioneered the development of some of the first approved therapies in the field, Nvelop is uniquely positioned to unlock the promise of genetic medicines.”.

Nvelop首席执行官杰夫·沃尔什（JeffWalsh）说：“在体内有效地将治疗药物输送到多种靶细胞的挑战极大地限制了遗传医学领域的发展。”。“凭借一流的技术、在细胞和基因治疗方面有着深厚记录的科学联合创始人以及在该领域率先开发一些首批批准疗法的团队的结合，Nvelop处于独特的地位，可以解开遗传药物的希望。”

Nvelop’s modular platforms are based on two in vivo validated delivery approaches developed at the Broad Institute of MIT and Harvard, and Massachusetts General Hospital by luminaries in the gene editing field – co-founders David Liu, Ph.D., and Keith Joung, M.D., Ph.D. These novel approaches are designed to realize the potential of genetic medicines by addressing the limitations of currently available delivery platforms with improved:.

Nvelop的模块化平台基于麻省理工学院和哈佛大学布罗德研究所以及麻省总医院开发的两种经过体内验证的递送方法，这两种递送方法由基因编辑领域的杰出人士共同创始人David Liu博士和Keith Joung博士开发。这些新方法旨在通过改进现有递送平台的局限性来实现遗传药物的潜力：

Delivery efficiency, enabling potent therapies to target diseases across multiple tissues in which a high degree of activity is required for clinical benefit;

交付效率，使有效的治疗能够针对多种组织中的疾病，其中临床获益需要高度的活性；

Tissue specificity, driving targeted in vivo delivery to cells and tissues that have been historically difficult to reach;

组织特异性，驱动靶向体内递送至历史上难以到达的细胞和组织；

Cargo diversity, allowing delivery of a wide range of cargo types and sizes, including transiently expressed proteins (e.g., base and prime editor ribonucleoproteins – or RNPs); and

货物多样性，允许交付各种货物类型和大小，包括瞬时表达的蛋白质（例如，碱基和主要编辑核糖核蛋白-或RNP）；和

Safety advantages, expanding the number of diseases treatable with genetic medicines. Increased safety is achieved by optimized RNP cargoes and intricately engineered particles with the potential to be fully humanized.

安全优势，扩大了基因药物可治疗的疾病数量。通过优化的RNP货物和复杂的工程颗粒，可以实现完全人性化，从而提高安全性。

One of Nvelop’s platform technologies, with in vivo data, has been published in prestigious peer-reviewed journals, including Cell (2022) and Nature Biotechnology (2024). In vivo data for the second platform is expected to be disclosed at one or more scientific meetings this year.

拥有体内数据的Nvelop平台技术之一已在著名的同行评审期刊上发表，包括Cell（2022）和Nature Biotechnology（2024）。第二个平台的体内数据预计将在今年的一次或多次科学会议上披露。

“At Nvelop, we stand on the cusp of an extraordinary journey, as our delivery technologies have the potential to be truly disruptive,” said Melissa Bonner, Ph.D., Nvelop’s Chief Scientific Officer. “I’m excited to be a part of a team committed to building a future in which curative therapies are more broadly accessible.”.

Nvelop首席科学官梅丽莎·邦纳博士说：“在Nvelop，我们正站在一段非凡旅程的尖端，因为我们的交付技术有可能真正具有颠覆性。”。“我很高兴成为一个团队的一员，这个团队致力于建立一个未来，在这个未来，治疗疗法可以更广泛地获得。”

In addition to its distinguished scientific co-founders, Nvelop has assembled a team of experienced scientists, industry executives, and company builders with a collective reputation for innovation and business excellence. Nvelop was founded in 2022, having raised an initial round of $100 million.

除了杰出的科学联合创始人外，Nvelop还组建了一支由经验丰富的科学家、行业高管和公司建设者组成的团队，他们在创新和商业卓越方面享有集体声誉。Nvelop成立于2022年，最初筹集了1亿美元。

“At Nvelop, we’re building a culture of curiosity, trust and mutual respect, where we are invested in each employee’s growth, because we believe that great science that brings benefit to patients is only possible in an environment that fosters the best in everyone,” added Walsh.

沃尔什补充道：“在Nvelop，我们正在建立一种好奇心、信任和相互尊重的文化，我们将投资于每位员工的成长，因为我们相信，只有在培养每个人最好的环境中，才能使伟大的科学造福于患者。”

Executive team:

执行团队：

Jeff Walsh - Chief Executive Officer. Jeff brings more than 30 years of leadership experience with high growth, public and private life sciences companies, including as Chief Financial Officer and Strategy Officer of bluebird bio

杰夫·沃尔什（JeffWalsh）——首席执行官。杰夫在高增长的公共和私人生命科学公司拥有30多年的领导经验，包括担任蓝鸟生物的首席财务官和战略官

​Melissa Bonner, Ph.D. - Chief Scientific Officer. Melissa brings 20 years of cell and gene therapy experience, most recently as Head of Research of bluebird bio, where she led a team that was instrumental in securing FDA approvals for ZYNTEGLO™, SKYSONA™, and LYFGENIA™

​梅丽莎·邦纳博士，首席科学官。梅丽莎拥有20年的细胞和基因治疗经验，最近担任蓝鸟生物研究负责人，她领导的团队有助于确保FDA批准ZYNTEGLO™、SKYSONA™和LYFGENIA™

Lisa McGrath - Chief People Officer. Lisa has more than 20 years of experience driving impactful people and culture initiatives, most recently as Chief People Officer at Surface Oncology

丽莎·麦格拉斯（LisaMcGrath）——首席人事官。Lisa拥有20多年推动有影响力的人才和文化计划的经验，最近担任表面肿瘤学首席人事官

Board of Directors – Nvelop’s board of directors comprises leaders in the gene and cell therapy fields, and investors from top venture capital firms:

董事会–Nvelop的董事会由基因和细胞治疗领域的领导者以及顶级风险投资公司的投资者组成：

Nvelop Therapeutics was founded in 2022 to address the challenge of efficiently delivering therapeutic cargoes to target cells in vivo. Nvelop’s next-generation platforms enable highly efficient and cell-specific in vivo delivery of a wide range of cargoes to many types of target cells. The two platforms were independently developed in the labs of scientific co-founders and gene editing pioneers Dr.

Nvelop Therapeutics成立于2022年，旨在解决将治疗性货物有效递送至体内靶细胞的挑战。Nvelop的下一代平台能够高效和细胞特异性地将多种货物体内递送至多种类型的靶细胞。这两个平台是在科学联合创始人和基因编辑先驱Dr。

David Liu of the Broad Institute of MIT and Harvard, and Dr. Keith Joung at Massachusetts General Hospital. With its own pipeline of therapeutics and through strategic collaborations, Nvelop aims to use these programmable, non-viral platforms to transform delivery for a broad range of genetic medicines and modalities in order to treat many previously undruggable diseases.

麻省理工学院和哈佛大学布罗德研究所的大卫·刘和麻省总医院的基思·琼博士。通过自己的治疗方法和战略合作，Nvelop旨在利用这些可编程的非病毒平台来改变广泛遗传药物和方式的交付方式，以治疗许多以前无法治疗的疾病。

Based in Cambridge, Mass., Nvelop is backed by top life science investors including Newpath Partners, Atlas Venture, F-Prime Capital, 5AM Ventures, GV, and ARCH Venture Partners. For more information, visit www.nveloptx.com or follow us on LinkedIn, X (Twitter), and Instagram..

Nvelop总部位于马萨诸塞州剑桥市，由包括Newpath Partners、Atlas Venture、F-Prime Capital、5AM Ventures、GV和ARCH Venture Partners在内的顶级生命科学投资者提供支持。有关更多信息，请访问www.nveloptx.com或在LinkedIn、X（Twitter）和Instagram上关注我们。